Saturday, February 4, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Notable Contracts: DynPort Nerve Agent Countermeasure Development

by Global Biodefense Staff
May 13, 2013

The Department of Defense this week announced a notable contract award related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense:

Dynport Vaccine Company, LLC, a CSC company, was awarded a $156,621,207.00 cost-reimbursement type contract action for the Development and FDA Licensure of a Bioscavenger Prophylactic.

The countermeasure will increase the likelihood that a Warfighter will maintain operational effectiveness following nerve agent exposure, specifically a drug or biologic intended for use prior to an exposure to nerve agent. It is anticipated that the countermeasure shall decrease incapacitation and death associated with nerve agent poisoning. Specifically, when administered prior to nerve agent exposure, the countermeasure should prevent injury by binding and sequestering or degrading nerve agent in the circulatory system before it can reach the nervous system. 

The award was issued by Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division. 

Background

The U.S. Army has been researching naturally occurring human enzyme called butyrylcholinesterase for their potential as a chemical agent countermeasure. Nicknamed “BioScavenger,” the enzyme works by capturing the nerve agent as it enters the body, before it can reach its physiological target and negating the danger.  

In 2005, the U.S. Department of Defense (DoD) Chemical Biological Medical Systems – Medical Identification and Treatment Systems (CMBS-MITS), building on the work of Army scientists, awarded a contract to DynPort for further advance development of human plasma-derived BioScavenger as a pre-exposure therapeutic, or prophylactic, against chemical nerve agents.

Under this funding effort, DynPort led a collaborative effort with Baxter International, Inc., a leader in the development and manufacturing of plasma-derived therapeutics. Baxter completed process development and manufacturing of a candidate therapeutic to be used in a Phase 1 clinical trial conducted by Dynport. Baxter developed, manufactured, characterized and preclinically tested the candidate protein used in the trial, and served as the Sponsor. Both CBMS-MITS scientists and Baxter personnel were an integral part of the BioScavenger team from the beginning, and worked in concert with DynPort to address program challenges.

The BioScavenger clinical trial material was manufactured using Baxter’s proprietary commercial plasma fractionation process. Phase 1 clinical trials, or “first-in-human” trials of BioScavenger were conducted, testing both intravenous (IV) and intramuscular (IM) routes of administration. While IV administration provides the more rapid response typically needed for post-exposure treatment, IM administration lends itself more readily to the possibility of self-administration, as might be necessary in a combat setting.

Read more at the CSC: Successful Partnership Tests Chemical Defense Countermeasures

Source: FBO.gov

Tags: AwardsBioscavengersJPEO-CBRND

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC